Cam Gallagher Sells 10,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Stock

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Rating) President Cam Gallagher sold 10,000 shares of the stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $24.15, for a total transaction of $241,500.00. Following the completion of the sale, the president now directly owns 352,011 shares in the company, valued at $8,501,065.65. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Cam Gallagher also recently made the following trade(s):

• On Thursday, January 5th, Cam Gallagher sold 10,000 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $21.02, for a total transaction of $210,200.00.
• On Tuesday, November 15th, Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $22.77, for a total transaction of $284,625.00.
• On Monday, November 7th, Cam Gallagher sold 12,500 shares of Zentalis Pharmaceuticals stock. The stock was sold at an average price of $23.67, for a total transaction of $295,875.00.

Zentalis Pharmaceuticals Stock Performance

NASDAQ ZNTL opened at $23.17 on Friday. The firm’s 50 day moving average price is $20.78 and its 200-day moving average price is $24.18. Zentalis Pharmaceuticals, Inc. has a 52-week low of $17.33 and a 52-week high of $61.71. The company has a market cap of $1.32 billion, a PE ratio of -4.91 and a beta of 1.77.

Zentalis Pharmaceuticals (NASDAQ:ZNTL – Get Rating) last released its quarterly earnings data on Wednesday, November 9th. The company reported ($0.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.19. On average, analysts forecast that Zentalis Pharmaceuticals, Inc. will post -4.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Assetmark Inc. boosted its stake in Zentalis Pharmaceuticals by 337.3% in the second quarter. Assetmark Inc. now owns 1,054 shares of the company’s stock valued at $30,000 after acquiring an additional 813 shares in the last quarter. Captrust Financial Advisors boosted its stake in Zentalis Pharmaceuticals by 15,160.0% in the first quarter. Captrust Financial Advisors now owns 763 shares of the company’s stock valued at $35,000 after acquiring an additional 758 shares in the last quarter. Great West Life Assurance Co. Can acquired a new stake in Zentalis Pharmaceuticals in the third quarter valued at approximately $48,000. Point72 Hong Kong Ltd acquired a new stake in Zentalis Pharmaceuticals in the third quarter valued at approximately $59,000. Finally, Metropolitan Life Insurance Co NY lifted its stake in shares of Zentalis Pharmaceuticals by 24.1% during the third quarter. Metropolitan Life Insurance Co NY now owns 2,828 shares of the company’s stock worth $61,000 after buying an additional 550 shares during the period.

Analyst Ratings Changes

A number of equities analysts have recently commented on ZNTL shares. SVB Leerink reduced their target price on shares of Zentalis Pharmaceuticals from $42.00 to $27.00 and set an “outperform” rating on the stock in a research report on Thursday, November 10th. Oppenheimer reduced their target price on shares of Zentalis Pharmaceuticals from $80.00 to $50.00 and set an “outperform” rating on the stock in a research report on Thursday, November 10th. Morgan Stanley reduced their target price on shares of Zentalis Pharmaceuticals from $60.00 to $55.00 and set an “overweight” rating on the stock in a research report on Friday, November 11th. Wedbush reduced their target price on shares of Zentalis Pharmaceuticals from $51.00 to $32.00 and set an “outperform” rating on the stock in a research report on Monday, November 14th. Finally, Wells Fargo & Company reduced their target price on shares of Zentalis Pharmaceuticals from $52.00 to $46.00 in a research report on Monday, November 14th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $46.56.

Zentalis Pharmaceuticals Company Profile

(Get Rating)

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker.